In the context of advanced HCC, a study on 128 sorafenib-treated HCC patients (93% Child–Pugh class A) divided over a discovery and validation cohort evaluated the prognosis value of pretreatment serum IL-6 levels. Here, IL6 is linked to hepatocellular carcinoma.